Alerts will be sent to your verified email
Verify EmailALBERTDAVD
Albert David
|
Syncom Formulations
|
Venus Remedies
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
R&D as a % of Total Sales
|
0.56 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
10.91 % | 9.0 % | 3.75 % |
5yr average Equity Multiplier
|
1.72 | 1.5 | 1.64 |
5yr Average Asset Turnover Ratio
|
0.72 | 0.91 | 0.78 |
5yr Avg Net Profit Margin
|
9.03 % | 6.98 % | 2.2 % |
Price to Book
|
1.95 | 4.76 | 0.93 |
P/E
|
10.31 | 48.7 | 15.06 |
5yr Avg Cash Conversion Cycle
|
-57.55 Days | 87.47 Days | 62.86 Days |
Inventory Days
|
47.31 Days | 26.14 Days | 110.85 Days |
Days Receivable
|
28.0 Days | 116.42 Days | 37.87 Days |
Days Payable
|
100.06 Days | 73.26 Days | 50.32 Days |
5yr Average Interest Coverage Ratio
|
55.29 | 49.11 | 42.3 |
5yr Avg ROCE
|
14.73 % | 13.31 % | 5.53 % |
5yr Avg Operating Profit Margin
|
15.62 % | 12.52 % | 12.68 % |
5 yr average Debt to Equity
|
0.01 | 0.16 | 0.38 |
5yr CAGR Net Profit
|
6.31 % | 15.51 % | n/a |
5yr Average Return on Assets
|
6.37 % | 6.01 % | 3.42 % |
Shareholdings
|
|||
Promoter Holding
|
62.13 % | 50.57 % | 41.76 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.88 % | 9.39 % | 5.87 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Albert David
|
Syncom Formulations
|
Venus Remedies
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Dosage Form Break-Up
|
Dosage Form Break-Up
|
-
|
-
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|